摘要
目的探讨骨化三醇治疗桥本甲状腺炎的临床效果。方法选取辽阳市中心医院新城医院2019年1月至2021年1月收治的110例桥本甲状腺炎患者,采取随机数字表法分为对照组与观察组,各55例。对照组给予左旋甲状腺素片治疗,观察组在对照组的基础上加用骨化三醇治疗。比较两组的临床疗效、治疗前后甲状腺激素指标、抗甲状腺球蛋白抗体(TGAb)、抗甲状腺过氧化物酶抗体(TPOAb)浓度水平,同时观察治疗期间的不良反应。结果观察组的临床总有效率高于对照组,差异有统计学意义(P<0.05)。观察组治疗后的游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)水平高于对照组,促甲状腺激素(TSH)水平、TGAb及TPOAb浓度均低于对照组,差异有统计学意义(P<0.05)。两组治疗期间均未出现血常规、尿常规、肝肾功能指标病变等不良反应。结论在左旋甲状腺素片的基础上加用骨化三醇治疗桥本甲状腺炎,可获得显著的临床疗效,能够促进甲状腺激素水平改善,调节TgAb、TPOAb浓度,且治疗期间无明显不良反应,安全性较高。
Objective To explore the clinical effect of Calcitriol in the treatment of Hashimoto thyroiditis.Methods A total of 110 patients with Hashimoto thyroiditis treared in Xincheng Hospital of Liaoyang Central Hospital selected from January 2019 to January 2021 were selected and divided into the control group and the observation group according to random number table method,with 55 cases in each group.The control group was treated with Levothyroxine Tablets,and the observation group was treated with Calcitriol on the basis of the control group.The clinical efficacy,thyroid hormone indexes,concentration of anti-thyroglobulin antibody(TGAb)and anti-thyroid peroxidase antibody(TPOAb)before and after treatment were compared between the two groups,and the adverse reactions during treatment were observed.Results The total clinical effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).The levels of free triiodothyronine(FT3)and free thyroxine(FT4)in the observation group after treatment were higher than those in the control group,and the levels of thyroid stimulating hormone(TSH),TGAb and TPOAb in the observation group after treatment were lower than those in the control group,the differences were statistically significant(P<0.05).During the treatment period,there were no adverse reactions such as blood routine,urine routine,liver and kidney function index lesions in the two groups.Conclusion The addition of Calcitriol on the basis of Levothyroxine Tablets in the treatment of Hashimoto thyroiditis can achieve significant clinical effects,can promote the improvement of thyroid hormone levels,adjust the concentration of TGAb and TPOAb,and there is no obvious adverse reaction during the treatment period,with high safety.
作者
孙闯
SUN Chuang(Department of Endocrinology,Xincheng Hospital of Liaoyang Central Hospital,Liaoning Province,Liaoyang 111000,China)
出处
《中国当代医药》
CAS
2022年第7期89-92,共4页
China Modern Medicine